Understand the main reasons why trial sponsors may fail to comply with global disclosure regulations or the expectations of transparency advocates, learn how leading sponsors are taking control of their transparency obligations, and see examples of tools that will help you ensure consistent compliance with disclosure regulations and policies.
Other content in this Stream
Mike Wenger, TrialScope Vice President of Patient Engagement, has been named one of the 2020 PM360 ELITE 100 in the Patient Advocates category for spearheading the industry-first TrialScope Connect.
TrialScope’s “Real Patient Stories: The Trials of Finding Clinical Trials” video won a Silver award in the WEGO Health Patient-Choice Awards for Most Authentic Use of Patients in a Marketing Campaign.
CoronaClinicalTrials.com offers updated COVID-19 research information from government sources plus educational material on clinical trials.
EMD Serono’s Clinical Trial Transparency website, powered by the TrialScope Engage™ platform, has been named a finalist for the 5th Annual Citeline Awards.
Craig Lipset and Scott Ballenger have joined the advisory board of TrialScope Connect, a clinical trial recruitment collective addressing the challenges of accurately matching patients to trials.
Mike Wenger, TrialScope VP of Patient Engagement, makes a few healthcare tech predictions for 2020.
Mike Wenger, Vice President of Patient Engagement, talks about ways to improve the clinical trials process by focusing more on the patients who are being recruited, tracked and retained.
PM360, a pharmaceutical trade magazine, has selected TrialScope Engage™ Embedded technology as one of the most innovative healthcare products for 2019.
TrialScope has worked with EMD Serono, the North American branch of the healthcare business of Merck KGaA, and CISCRP to launch a new clinical trials website, https://clinicaltrials.emdgroup.com.
Beyond regulatory compliance, transparency is simply good business. For starters, it puts companies in a favorable light with the public and investors.